Subtype or state? Rethinking the apCAF paradox and fibroblast plasticity in gastrointestinal cancers
- 1Department of Gastroenterology, First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine
- 2The First Clinical Medical College, Guizhou University of Traditional Chinese Medicine
Abstract
Antigen-presenting cancer-associated fibroblasts (apCAFs), commonly defined by MHC class II molecules, CD74, and related transcriptional programs, exhibit divergent functions across gastrointestinal tumors. In pancreatic ductal adenocarcinoma, mesothelium-derived apCAFs promote regulatory T-cell differentiation and suppress effector responses, whereas their abundance in gastric cancer is associated with earlier-stage disease, longer survival, and improved immunotherapy responses. This paradox may reflect microenvironmental context and classifications that conflate transcriptional state, cellular origin, and immune function. apCAFs may therefore represent reversible, context-dependent states defined by origin, MHC class II-restricted antigen presentation, and co-stimulatory capacity. We propose a two-layer model that has not been validated in apCAFs. In this model, the chromatin accessibility of CIITA, CD40, CD80, and CD86 constructs a functional licensing range, while interferon - γ (IFN - γ), interleukin-1 (IL-1), and transforming growth factor - β (TGF - β) guide the formation of specific phenotypes within this range. Insufficient co-stimulation may favor immune tolerance; activation of co-stimulatory programs may support CD4 ⁺ T-cell help and CD8 ⁺ T-cell infiltration. Treatment-induced changes in CAF composition may reflect selective survival or genuine state transitions. Distinguishing these mechanisms requires lineage tracing, longitudinal single-cell transcriptomic and chromatin profiling, and patient-derived organoid–fibroblast co-cultures. Neoadjuvant therapy and serial endoscopic sampling provide feasible settings for capturing transient states. This framework supports replacing broad CAF depletion with temporally and state-informed functional reprogramming.
Related
- The consolidation paradox: rethinking thoracic radiotherapy in extensive-stage small cell lung cancer in the immunotherapy era
- Mapping fibroblast plasticity across non-cancer lung diseases at single-cell resolution.
- Rethinking evidence generation in gastrointestinal cancer treatment research: the need for both high-quality interventional and observational evidence
- ISG15+ Müller glial subtype contributes to early blood–retinal barrier breakdown in diabetic retinopathy
- Distinct Molecular Landscape and Clinical Subtype of HPV-Positive Esophageal Squamous Cell Carcinoma
BibTeX
@article{yu2026subtype,
title = {{Subtype or state? Rethinking the apCAF paradox and fibroblast plasticity in gastrointestinal cancers}},
author = {Zhilin Yu and Dingnan Hu and Zhenxiang An},
journal = {Frontiers in Oncology},
year = {2026},
month = oct,
doi = {10.3389/fonc.2026.2000409},
url = {https://www.frontiersin.org/articles/10.3389/fonc.2026.2000409/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Subtype or state? Rethinking the apCAF paradox and fibroblast plasticity in gastrointestinal cancers
AU - Zhilin Yu
AU - Dingnan Hu
AU - Zhenxiang An
PY - 2026
DA - 2026/10/26
JO - Frontiers in Oncology
DO - 10.3389/fonc.2026.2000409
UR - https://www.frontiersin.org/articles/10.3389/fonc.2026.2000409/full
AB - Antigen-presenting cancer-associated fibroblasts (apCAFs), commonly defined by MHC class II molecules, CD74, and related transcriptional programs, exhibit divergent functions across gastrointestinal tumors. In pancreatic ductal adenocarcinoma, mesothelium-derived apCAFs promote regulatory T-cell differentiation and suppress effector responses, whereas their abundance in gastric cancer is associated with earlier-stage disease, longer survival, and improved immunotherapy responses. This paradox may reflect microenvironmental context and classifications that conflate transcriptional state, cellular origin, and immune function. apCAFs may therefore represent reversible, context-dependent states defined by origin, MHC class II-restricted antigen presentation, and co-stimulatory capacity. We propose a two-layer model that has not been validated in apCAFs. In this model, the chromatin accessibility of CIITA, CD40, CD80, and CD86 constructs a functional licensing range, while interferon - γ (IFN - γ), interleukin-1 (IL-1), and transforming growth factor - β (TGF - β) guide the formation of specific phenotypes within this range. Insufficient co-stimulation may favor immune tolerance; activation of co-stimulatory programs may support CD4 ⁺ T-cell help and CD8 ⁺ T-cell infiltration. Treatment-induced changes in CAF composition may reflect selective survival or genuine state transitions. Distinguishing these mechanisms requires lineage tracing, longitudinal single-cell transcriptomic and chromatin profiling, and patient-derived organoid–fibroblast co-cultures. Neoadjuvant therapy and serial endoscopic sampling provide feasible settings for capturing transient states. This framework supports replacing broad CAF depletion with temporally and state-informed functional reprogramming.
SN - 2234-943X
ER -